Clinical implications of nintedanib pharmacokinetics in patients with pulmonary fibrosis
Nintedanib dose was significantly associated with FVC loss. However, no significant relationship between nintedanib exposure and the occurrence of DLTs was found in this real-world population, and no therapeutic window could be established. The findings in this study indicate that nintedanib is an unsuitable candidate for performing TDM.
Authors
- Bram C. Agema (ORCID: https://orcid.org/0000-0003-1825-2911)
- Birgit C. P. Koch (ORCID: https://orcid.org/0000-0002-1202-3643)
- Sebastian D. T. Sassen
- J.R. Miedema
- Marlies Wijsenbeek (ORCID: https://orcid.org/0000-0002-4527-6962)
- L. Seuren
- Stijn L.W. Koolen (ORCID: https://orcid.org/0000-0002-0973-7530)
- Ron H.J. Mathijssen (ORCID: https://orcid.org/0000-0001-5667-5697)
- M Berrich
- G. Veerman (ORCID: https://orcid.org/0000-0002-4594-3374)
Institutions
- Erasmus MC Cancer Institute (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Biomedicine & Pharmacotherapy
- Published
- 2024-08-26
- DOI
- https://doi.org/10.1016/j.biopha.2024.117341
- Citations
- 2
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.84